Summary
Eli Lilly and Company (LLY) filed an 8-K on January 30, 2020, to report its financial results for the fourth quarter and full fiscal year ended December 31, 2019. The primary purpose of this filing was to furnish a press release containing these unaudited financial results. Investors should note that this information is being furnished and not deemed 'filed' for certain regulatory purposes, meaning it doesn't carry the same legal implications under Section 18 of the Exchange Act. However, it serves as the official disclosure of Lilly's performance during the specified periods. The attached press release (Exhibit 99.1) is the key document for investors seeking details on Lilly's operational and financial performance. While the 8-K itself is brief, it directs investors to this exhibit for crucial metrics such as revenue, earnings per share, and potentially forward-looking guidance, which are vital for evaluating the company's current health and future prospects. Investors should consult Exhibit 99.1 for a comprehensive understanding of the reported financial outcomes.
Key Highlights
- 18-K filing on January 30, 2020, reports Q4 and FY 2019 results.
- 2Information furnished, not filed, under Section 18 of the Exchange Act.
- 3Exhibit 99.1 contains the press release with detailed financial results.
- 4Press release dated January 30, 2020, announces the Q4 and FY 2019 earnings.
- 5This filing serves as the official disclosure of the company's financial performance for the period.
- 6Investors should refer to Exhibit 99.1 for specific financial metrics and operational details.